Real world study of Innovator Infliximab (REMICADE) and Biosimilar Infliximab in a Treatment Naive Turkish Rheumatologic Disease Population
Phase of Trial: Phase III
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatic disorders
- Focus Therapeutic Use
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.
- 28 Nov 2016 New trial record
- 14 Nov 2016 Real-World data published in a Janssen Biotech media release.